Receptor Life Sciences Announces Publication of Proof-of-Principle Clinical Pharmacokinetics Study of RLS103 (Inhaled Dry Powder CBD)
SEATTLE–(BUSINESS WIRE)–Receptor Life Sciences (RLS), a pharmaceutical company developing innovative therapies to address central nervous system disorders, announced the publication of a manuscript in the Journal of Pharmaceutical Sciences. The…
Details